Abstracts tagged "evidence-based practice and treatment"

Abstract Number: 2280 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendations for the Management of Cryopyrin Associated Periodic Syndromes (CAPS)
Nienke ter Haar¹, Marlen Oswald², Luca Cantarini³, Marco Gattorno⁴, Michael Hofer⁵, Isabelle Kone-Paut⁶, Jordi Anton Lopez⁷, Karyl Barron⁸, Paul Brogan⁹, Joost Frenkel¹⁰, Caroline Galeotti¹¹, Gilles Grateau¹², Veronique Hentgen¹³, Tilmann Kallinich¹⁴, Helen Lachmann¹⁵, Huri Ozdogan¹⁶, Seza Ozen¹⁷, Ricardo Russo¹⁸, Anna Simon¹⁹, Yosef Uziel²⁰, Carine Wouters²¹, Brian Feldman²², Bas Vastert¹⁰, Nico Wulffraat²³, Susanne Benseler²⁴ and Jasmin Kuemmerle-Deschner²⁵, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²University Hospital Tuebingen, Tuebingen, Germany, ³University of Siena, Siena, Italy, ⁴Pediatric Rheumatology, Instituto Giannina Gaslini, Genoa, Italy, ⁵Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ⁷pediatric Rheumatology, University Childrenxs Hospital, Barcelona, Spain, ⁸NIH, Bethesda, MD, ⁹Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹⁰University Medical Center Utrecht, Utrecht, Netherlands, ¹¹Bicêtre Hospital, University of Paris SUD, Paris, France, ¹²Service De Médecine Interne, Hopital Tenon, Paris, France, ¹³Versailles Hospital, Le Chesnay Cedex, France, ¹⁴Charite, University Medicine Berlin, Berlin, Germany, ¹⁵UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁷Hacettepe University, Ankara, Turkey, ¹⁸Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁹Radboudumc, Nijmegen, Netherlands, ²⁰Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ²¹University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²³Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²⁴The Hospital for Sick Children, Toronto, ON, Canada, ²⁵Pediatrics, University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose Cryopyrin-associated periodic syndromes (CAPS) is a group of rare monogenetic autoinflammatory disorders. Evidence-based guidelines are lacking and management is mostly based on physician’s experience. Consequently,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].